ArticleBritish journal of cancer2018

Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2.

Rastislav Bahleda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.